Browsing by Author "Karakaya, Amine Aktar"

Now showing 1 - 3 of 3

Abnormal Uterine Bleeding in Adolescent Girls Retrospective Study
(Brieflands, 2025) Ozalkak, Servan; Yildirim, Ruken; Karakaya, Amine Aktar; Tas, Funda Feryal; Oncel, Kahraman; Okur, Nurettin; Ozbek, Mehmet Nuri
Background: Abnormal uterine bleeding (AUB) is the most common reason for gynecology-related hospital admissions in adolescence. Objectives: The present single-center study aimed to evaluate the diagnosis distribution in adolescents with AUB and to compare the clinical features and treatments of patients with hemoglobin levels below and above 10 g/dL. Methods: The present single-center study retrospectively collected demographic and epidemiological data from adolescents aged 10 - 18 years presenting to our institution with a diagnosis of AUB. Patient data were extracted from electronic medical records and analyzed using SPSS software. Descriptive statistics, including frequency, percentage, mean, standard deviation (SD), median, and interquartile range (IQR), were calculated. Patients were classified according to hemoglobin levels (< 10 g/dL as group 1 and >= 10 g/dL as group 2). Results: Among 167 adolescent patients, 35.9% had hemoglobin levels below 10 g/dL. Hospitalization rates were significantly higher in group 1 (86.4%) compared to group 2 (2.8%) (P < 0.001). The most common causes of AUB were anovulation (84.4%) and polycystic ovary syndrome (PCOS) (11.4%). The primary treatments included combined oral contraceptives (COCs) with iron supplementation (45.5%) and iron alone (28.7%). Erythrocyte transfusion (ERT) was performed in 18% of cases, predominantly in group 1. This study is limited by the lack of a standardized quality of life assessment tool for AUB. The single-center design and retrospective data collection may limit the generalizability of the findings and introduce selection bias, respectively. Conclusions: Anovulation and PCOS are the main causes of AUB in adolescents. Patients with hemoglobin levels below 10 g/dL and active bleeding should be evaluated carefully, as ERT may be necessary. A wide differential diagnosis should always be considered when managing adolescent AUB.
Çocukluk Çağında Yeni Tanı Almış 140 Diyabet Olgusunun Tanı Tipleri ve Klinik Özellikleri: Tek Merkez Deneyimi
(2025) Yıldırım, Ruken; Ozbek, Mehmet Nuri; Trabzon, Gül; Orhan, Özhan; Karakaya, Amine Aktar
Amaç: Çocukluk çağındaki diyabetes mellitusun (DM) çoğunluğunu tip 1 diyabet (T1DM) oluşturur. Ancak son yıllarda tip 2 diyabetes mellitus (T2DM) sıklığında ve monogenik diyabet (MD) tanısı koymada artış gözlenmektedir. Bu çalışmada 0-18 yaş arasında tanı konulan diyabetli hastalarda klinik ve laboratuvar bulgularının, DM tiplerinin değerlendirilmesi amaçlandı. Gereç ve yöntem: Çalışmada kliniğimizde DM tanısı alan 140 hasta retrospektif olarak değerlendirildi. Bulgular: Üç yıllık süreçte 140 hastaya (76 erkek, %54,3) diyabet tanısı konuldu. Hastaların ortalama tanı yaşı 10±4,19 yıldı. Hastaların %93,6'sına T1DM, %2,8'ine T2DM, %3,6'sına MD tanısı konuldu. Tip 1 diyabetes mellitus vakalarının 5-9 (%36,6) ve 10-14 (%37,4) yaş gruplarında zirve yaptığı görüldü. Diyabetik ketoasidoz (DKA) prevalansı %61,8 idi. Yine bu olguların %64,9'u sonbahar/kış aylarında tanı aldı. Tip2 diyabetli hastaların %75'i kadındı ve ortalama tanı yaşı 15,05±1,11 idi. Monogenik diyabetli olgularının ikisi neonatal DM, ikisi GCK-MODY ve biri CEL-MODY idi. Sonuç: Çocukluk çağı diyabet vakalarının çoğunluğu T1DM olmasına rağmen, özellikle obez ergenlerde T2DM sıklığı artma eğilimindedir. Otoantikor pozitif T1DM’li hastalarda da obezitenin olabileceği akılda tutulmalıdır. Tip1 diyabet olgularının daha çok kış mevsiminde, 10-14 yaş grubunda başvurduğu ve DKA sıklığının yüksek olduğu saptandı. Monogenik diyabet şüphesi olan olgulara genetik inceleme yapılmalıdır.
Final Height in Patients with Turner Syndrome Treated with Growth Hormone Therapy
(AVES, 2026) Aktar Karakaya, A.A.; Unal, E.; Yıldırım, R.; Özalkak, Ş.; Taş, F.F.; Özbek, M.N.; Karakaya, Amine Aktar
Objective: Turner syndrome (TS) is the most common sex chromosome abnormality in girls. Short stature is the most distinctive feature. This study aimed to evaluate factors affecting final height (FH) in patients with TS who received growth hormone (GH) therapy and achieved their final height (FH). Materials and Methods: About 48 patients with TS who received GH therapy and reached their FH were included and examined retrospectively. Initial height, standard deviation score (SDS), FH, and FH SDS measurements of the patients were obtained. Additionally, factors affecting FH were analyzed. Results: Growth hormone was administered at a dose of 45.6 ± 6.2 (min-max: 34-69) μg/kg/day at a mean age of 11.7 ± 2.9 years. The duration of therapy was 4.3 ± 1.4 years. The mean FH of the patients was 147.80 ± 5.98 cm. About 29.2% (n=14) of the patients reached a height above the thirdpercentile. It was observed that GH therapy was initiated in these patients at a mean age of 10.3 ± 3.1 years; the initial height SDS was better. FH of 45,X and non-45,X cases were similar. Conclusion: In the study, GH therapy that was initiated at an early age in patients with good initial height SDS increased the gain of FH and FH SDS. Therefore, initiating GH therapy at an early age in patients with TS is important for height gain. ∆ Height SDS was better in cases that underwent late pubertal induction. Karyotype did not have a predictive effect on height prognosis. © 2026, AVES. All rights reserved.